AIDS Therapies

Zerit Approved For First-Line Treatment of HIV in Europe

Published in Virus Weekly, September 8th, 1997

Bristol-Myers Squibb Co., Princeton, New Jersey, announced that Zerit (stavudine), also known as d4T, received approval by the European Union for use in combination therapy in the first-line treatment of HIV in Europe.

The decision was based on recent data from clinical trials using Zerit in adults and children which demonstrate that combinations that include d4T can reduce viral load, often to undetectable levels, and increase the body's infection-fighting CD4 cells. Both are proven markers of disease improvement.

Zerit has been available in the U.S. since June 1994 and in Europe since May 1996, and is available in several other countries...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Virus Weekly

Source: Virus Weekly (1997-09-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry